Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights
Loading...All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
Insulin like growth factor binding protein 7 (IGFBP7) is a secreted extracellular matrix-associated binding protein encoded by IGFBP7 gene, expressed in endothelial, epithelial and stromal cell populations, localized to extracellular matrix and cell surface membrane microdomains. Distinct from canonical IGFBP paralogs, IGFBP7 relies on conserved N-terminal cysteine-rich domains to sequester insulin-like growth factor ligands, while simultaneously blocking growth factor receptor engagement to restrain proliferative and angiogenic signaling cascades. Under resting physiological tissue states, basal IGFBP7 secretion sustains balanced growth factor bioavailability without full suppression of physiological tissue renewal. Upon aberrant proliferative or angiogenic stimulation, accumulated extracellular IGFBP7 sequesters soluble IGF ligands to limit receptor activation, facilitating downstream growth arrest and endothelial stabilization programs. Unlike broad-spectrum extracellular binding proteins with general nutrient transport roles, IGFBP7 bears specialized growth-suppressive and anti-angiogenic functions that cannot be fully compensated by other IGFBP family members, linking soluble growth factor sequestration directly to tissue proliferative restriction pathways. Loss of functional IGFBP7 severely amplifies IGF-driven cell proliferation and pathological angiogenesis, while sustained IGFBP7 ligand sequestration restrains aberrant tissue overgrowth, establishing IGFBP7 as a core research target for secreted growth regulatory protein biology and anti-proliferative therapeutic compound screening.
IGFBP7 executes core growth factor sequestration function within extracellular matrix compartments, utilizing conserved cysteine-rich ligand-binding pockets to power selective capture of circulating insulin-like growth factor molecules. Conserved substrate recognition motifs exclusively bind IGF family growth factors, separating its ligand spectrum from unrelated extracellular matrix binding proteins distributed across tissue microenvironments. IGFBP7-mediated ligand sequestration bridges soluble growth factor diffusion and cell surface receptor inhibition, balancing physiological tissue renewal and pathological proliferative signal intensity according to local growth factor concentration. IGFBP7 participates in extensive physiological processes including endothelial stabilization, cell cycle arrest and angiogenic signal restriction. Deficient IGFBP7 secretion disrupts IGF ligand bioavailability control and impairs intrinsic tissue growth restriction capacity. Therefore, IGFBP7 represents a pivotal research target for IGF-binding protein superfamily study and anti-angiogenic compound screening.
Fig. 1 Workflow schematic of human pancreatic islet multi-omics research: RNA-seq identifies elevated IGFBP7 transcripts in T2D donor islets; single-cell transcriptomics and imaging confirm upregulated IGFBP7 in α and β cells; functional knockdown validates that α-cell-derived IGFBP7 acts in paracrine fashion to repress β-cell insulin exocytosis.1
The biological functions of IGFBP7 are focused on insulin-like growth factor binding, proliferative signal restriction and endothelial homeostasis control:
Creative Biolabs offers high-quality IGFBP7 proteins through optimized expression systems, including full-length secreted binding protein and isolated cysteine-rich ligand-binding domain variants. These products retain native IGF ligand sequestration biological activity, suitable for extracellular ligand-receptor interaction assays and anti-proliferative modulator screening. All IGFBP7 proteins undergo strict quality control to ensure consistent performance and reliable application across diverse research platforms.
Not finding the membrane protein product you need? Contact us to start your one-stop custom service!
Creative Biolabs provides custom-engineered IGFBP7 stable cell lines, including overexpression and blank control models. These cell lines are optimized for secreted binding protein expression profiling and IGF proliferative signal functional analysis. Each cell line undergoes stringent validation to ensure stable expression profiles and consistent functional performance in diverse experimental contexts.
Not finding the stable cell line product you need? Contact us to start your one-stop custom service!
High-specificity recombinant antibodies targeting IGFBP7 are developed via advanced antibody engineering technologies, with no cross-reactivity with other IGFBP family secreted binding proteins. These antibodies are validated for extracellular matrix and cell surface ligand localization detection and multi-tissue secretion profiling, and can be combined with IGF receptor detection reagents to analyze complete IGFBP7 growth regulatory complexes in endothelial and tumor cell models.
Not finding the recombinant antibody product you need? Contact us to start your one-stop custom service!
Beyond catalog products, Creative Biolabs offers specialized custom services for IGFBP7 research:
IGFBP7 is a secreted extracellular binding protein that sequesters insulin-like growth factors to inhibit proliferative and angiogenic receptor signaling.
IGFBP7 acts as a critical link between soluble growth factor bioavailability and tissue growth restriction, governing endothelial and tumor proliferative balance.
No, all IGFBP7 products and services are strictly for research use only, not intended for clinical diagnosis or treatment.
Offerings include full-length IGFBP7 secreted binding proteins, isoform-specific detection antibodies and custom stable cell lines for growth and endothelial research.
IGFBP7 proteins are validated via insulin-like growth factor ligand binding functional testing.
